Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC3153 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.000853 | uM | 10937.156 | 1.0865 | 1.1259 | 1.3582 | |
| HCC3153 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.00427 | uM | 10937.156 | 0.9776 | 0.9669 | 1.3582 | |
| HCC3153 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.0213 | uM | 10937.156 | 0.8677 | 0.8015 | 1.3582 | |
| HCC3153 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.107 | uM | 10937.156 | 0.8375 | 0.7551 | 1.3582 | |
| HCC3153 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.533 | uM | 10937.156 | 0.8783 | 0.8178 | 1.3582 | |
| HCC3153 | TNBC | Basal A | Everolimus | MTOR | MTOR | 2.67 | uM | 10937.156 | 0.7688 | 0.6480 | 1.3582 | |
| HCC3153 | TNBC | Basal A | Everolimus | MTOR | MTOR | 13.3 | uM | 10937.156 | 0.7541 | 0.6247 | 1.3582 | |
| HCC3153 | TNBC | Basal A | Everolimus | MTOR | MTOR | 66.7 | uM | 10937.156 | 0.0141 | -0.9134 | 1.3582 | |
| HCC38 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.000171 | uM | 11850.156 | 1.0202 | 1.0214 | 1.8757 | |
| HCC38 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.000853 | uM | 11850.156 | 0.9858 | 0.9848 | 1.8757 | |
| HCC38 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.00427 | uM | 11850.156 | 0.9096 | 0.9014 | 1.8757 | |
| HCC38 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.0213 | uM | 11850.156 | 0.7898 | 0.7636 | 1.8757 | |
| HCC38 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.107 | uM | 11850.156 | 0.6514 | 0.5914 | 1.8757 | |
| HCC38 | TNBC | Basal B | Everolimus | MTOR | MTOR | 0.533 | uM | 11850.156 | 0.6008 | 0.5242 | 1.8757 | |
| HCC38 | TNBC | Basal B | Everolimus | MTOR | MTOR | 2.67 | uM | 11850.156 | 0.6028 | 0.5270 | 1.8757 | |
| HCC38 | TNBC | Basal B | Everolimus | MTOR | MTOR | 13.3 | uM | 11850.156 | 0.5352 | 0.4331 | 1.8757 | |
| HCC38 | TNBC | Basal B | Everolimus | MTOR | MTOR | 66.7 | uM | 11850.156 | 0.0351 | -0.6644 | 1.8757 | |
| HCC70 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.000171 | uM | 10873.156 | 0.9519 | 0.9208 | 1.2215 | |
| HCC70 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.000853 | uM | 10873.156 | 0.9219 | 0.8712 | 1.2215 | |
| HCC70 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.00427 | uM | 10873.156 | 0.8178 | 0.6963 | 1.2215 | |
| HCC70 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.0213 | uM | 10873.156 | 0.7704 | 0.6154 | 1.2215 | |
| HCC70 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.107 | uM | 10873.156 | 0.6111 | 0.3363 | 1.2215 | |
| HCC70 | TNBC | Basal A | Everolimus | MTOR | MTOR | 0.533 | uM | 10873.156 | 0.6263 | 0.3635 | 1.2215 | |
| HCC70 | TNBC | Basal A | Everolimus | MTOR | MTOR | 2.67 | uM | 10873.156 | 0.5612 | 0.2462 | 1.2215 | |
| HCC70 | TNBC | Basal A | Everolimus | MTOR | MTOR | 13.3 | uM | 10873.156 | 0.5191 | 0.1693 | 1.2215 |